Design and Analysis of Phase I Trials in Clinical Oncology

Axel Benner, Lutz Edler and Gernot Hartung
Additional contact information
Axel Benner: German Cancer Research Center, Biostatistics Unit
Lutz Edler: German Cancer Research Center, Biostatistics Unit
Gernot Hartung: Mannheim Medical School, Oncological Center

Chapter 8 in Applied Statistics in the Pharmaceutical Industry, 2001, pp 189-216 from Springer

Abstract: Abstract In oncology the Phase I trial is the first occasion to treat cancer patients experimentally with a new drug with the aim of determining the drug treatment’s toxic properties, characterizing its dose-limiting toxicity (DLT), and estimating a maximum tolerable dose (MTD) as a benchmark dose for further clinical trials. Phase I trials are usually accompanied by an elaborate clinical pharmacology and the determination of individual pharmacokinetic parameters. Additionally, there is high interest in screening the drug for early signs of antitumor activity (Von Hoff et al., 1984). At this stage of drug development, a safe and efficacious dose in humans is unknown and information is available only from pre-clinical in vitro and in vivo studies. Therefore, patients are treated successively and in small groups, beginning at a low dose very likely to be safe (starting dose), and escalating progressively to higher doses until drug-related toxicity manifests and reaches DLT. Doses which induce a predetermined frequency of DLT among the patients treated, define the MTD (Bodey and Legha, 1987).

Keywords: Dose Level; Maximum Tolerable Dose; Toxicity Data; Common Toxicity Criterion; Population Pharmacokinetic Analysis (search for similar items in EconPapers)
Date: 2001
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-1-4757-3466-9_8

Ordering information: This item can be ordered from
http://www.springer.com/9781475734669

DOI: 10.1007/978-1-4757-3466-9_8

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().